Find projects about

The Catalyst Programme: Identifying which breast cancer patients could benefit from the drug palbociclib and how resistance to this drug can develop

Dr Rachael Natrajan and her team are investigating whether triple negative breast cancer patients could benefit from the CDK4/6 inhibitor drug palbociclib. They want to find ways to predict which groups of patients could benefit from this drug and whose cancer might develop resistance to it.

The Catalyst Progamme: Understanding the impact of the drug palbociclib on the spread of breast cancer to the bone, both by itself and in combination with other drugs.

New ways to treat breast cancer that has spread to the bones are urgently needed. Professor Ingunn Holen is investigating the effect of the drug palbociclib on the spread of breast cancer to bone. She aims to find new treatment combinations to improve options available for patients.  

""

The Catalyst Programme: Finding new ways to treat lobular breast cancer

The drugs crizotinib and lorlatinib have the potential to be new treatments for various forms of breast cancer. Professor Lord and his team will be investigating how these drugs work and using that information to work out the best way to use them to benefit patients.

Prof Nick Turner, from the Breast Cancer Now Catalyst research programme in the lab

The Catalyst Programme: ROLO trial for advanced lobular breast cancer

Professor Nicholas Turner and Dr Alicia Okines will lead a clinical trial of the drug crizotinib for patients with lobular breast cancer that has spread to other parts of the body. This trial, called the ROLO study, could lead to a much-needed new treatment for this type of breast cancer.